2019
Liraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteria
2012
Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth
Klingensmith GJ, Tamborlane WV, Wood J, Haller MJ, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW, Consortium P. Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat in Youth. The Journal Of Pediatrics 2012, 162: 330-334.e1. PMID: 22901739, DOI: 10.1016/j.jpeds.2012.06.058.Peer-Reviewed Original ResearchConceptsSevere diabetic ketoacidosisDiabetic ketoacidosisHemoglobin A1cIncidence of DKAInitial hemoglobin A1cNew-onset T1DPediatric Diabetes ConsortiumDiabetes-associated autoantibodiesLife-threatening complicationsOnset of T1DAfrican American raceType 1 diabetesNon-Hispanic CaucasiansClinical characteristicsEligible subjectsDiabetes onsetMean ageFamily historyPrivate health insuranceInclusion criteriaT1DMultivariate analysisYounger ageDemographic informationHealth insurance